Mitarbeiterbild

Prof. Dr. Michael Hoffmeister

Kommissarischer Abteilungsleiter, Gruppenleiter

Kommissarischer Abteilungsleiter
Gruppenleiter "Molekularpathologische Epidemiologie"

Forschungsschwerpunkte

Darmkrebsprävention
Screening & Früherkennung
Risikofaktoren und prognostische Faktoren
Molekularpathologische Epidemiologie
 

Wissenschaftliche Studien, Projekte

Studien-/ Verbundleiter: PEARL-Studie, PEARL-Verbund, DACHS-Studie, BLITZ-Studie, KolosSal-Studie, ASTER 1|2-Studie, IMPACT-3
Work Package PI: MiCCroBioTackle Consortium
Co-PI: GECCO Consortium, MOCCA
Weitere Studien und Projekte: UK Biobank, NAKO, DARIO-Studie, GEKKO-Studie, LEO-Studie
 

Weitere Aktivitäten und Mitgliedschaften

Helmholtz Health Prevention Task Force
ACED: International Alliance for Cancer Early Detection, Inequalities theme (Co-Lead)
NAKO: Nationale Kohorte, Expertengruppe Krebs
ECICC: European Commission Initiative on Colorectal Cancer
UNCAN.eu: a European initiative to better understand cancer
BBMRI: Biobanking and Biomolecular Resources Research Infrastructure
Promotionsausschuss (Dr. sc. hum.), Medizinische Fakultät, Universität Heidelberg
 

Aktuelle Doktoranden und Postdocs

Jie Ding
Mariem Hachani
Toktam Pour
Mary Jose Urruchúa Rodriguez
Durgesh Wankhede
Tanwei Yuan
 

Publikationen

Artikel in PubMed

ORCID profile


Ausgewählte Publikationen der letzten Jahre

Wankhede D, Halama N, Kloor M, Brenner H, Hoffmeister M. Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status. J Clin Oncol 2025, in press

Hoffmeister M, Seum T, Ludwig L, Brenner H. Performance of a smartphone-based stool test for use in colorectal cancer screening: population-based study. Clin Gastroenterol Hep 2025, in press

Wankhede D, Yuan T, Kloor M, Halama N, Brenner H, Hoffmeister M. Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2024;9(7):609-619.

Hoffmeister M, Cardoso R, Brenner H. Colonoscopy Screening and Colorectal Cancer Incidence and Mortality. N Engl J Med 2023;388(4):377-378.

Hoffmeister M. Interim evaluation of the colorectal cancer screening programme in the Netherlands. Lancet Gastroenterol Hepatol 2022;7(1):8-9.

Cardoso R, ..., Hoffmeister M, Brenner H. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol 2021;22(7):1002-1013.

Hoffmeister M, Brenner H, Amitay EL. Smoking Is Consistently Associated With Major Molecular Subtypes of Colorectal Cancer. Am J Gastroenterol 2021;116(5):1092-1093.

Hoffmeister M, Bläker H, Jansen L, Alwers E, Amitay EL, Carr PR, Kloor M, Herpel E, Roth W, Chang-Claude J, Brenner H. Colonoscopy and Reduction of Colorectal Cancer Risk by Molecular Tumor Subtypes: A Population-Based Case-Control Study. Am J Gastroenterol 2020;115(12):2007-2016.

Kather JN, Pearson AT, Halama N, Jäger D, Krause J, Loosen SH, Marx A, Boor P, Tacke F, Neumann UP, Grabsch HI, Yoshikawa T, Brenner H, Chang-Claude J, Hoffmeister M, Trautwein C, Luedde T. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med 2019;25(7):1054-56.

Amitay EL, Carr PR, Jansen L, Walter V, Roth W, Herpel E, Kloor M, Bläker H, Chang-Claude J, Brenner H, Hoffmeister M. Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. J Natl Cancer Inst 2019;111(5):475-83.

Lauby-Secretan B, Vilahur N, Bianchini F, Guha N, Straif K; International Agency for Research on Cancer Handbook Working Group. The IARC Perspective on Colorectal Cancer Screening. N Engl J Med 2018;378(18):1734-40.

Carr PR, Weigl K, Jansen L, Walter V, Erben V, Chang-Claude J, Brenner H, Hoffmeister M. Healthy Lifestyle Factors Associated With Lower Risk of Colorectal Cancer Irrespective of Genetic Risk. Gastroenterology 2018;155(6):1805-15.

Formular

Formulardaten werden geladen ...